What to expect

Primary Objective

The primary objective of this study is to determine the safety of extracorporeal albumin dialysis (ECAD) system containing albumin in the dialysis fluid recycled using the Hepalbin Charcoal Adsorbent to improve pruritus in patients with chronic liver disease.

Research Design and Methods

Patients with chronic liver disease who develop medically intractable pruritus will be evaluated for enrollment into the study. Each patient’s severity of itching will be self-assessed by the Visual Analogue Scale (VAS) tool and graded based on the severity of itching. In addition, each patient’s quality of life will be assessed using the following measures:

Length of treatment

ECAD therapy will consist of two 6-hour treatments over 3 days

Number of study visits

2

Follow-Up

1 month, 2 month & final 6-month follow-up